Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-LPA Antibody (R1L65)

Catalog #:   RHC33401 Specific References (49) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: WB
Accession: P08519
Overview

Catalog No.

RHC33401

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

WB: 1:1000-1:2000

Target

Apolipoprotein(a), LPA, Lp(a), Apo(a)

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08519

Applications

WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1L65

Data Image
  • Western blot
    Western blot analysis of ApoA expression in Human plasma lysate.
References

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial., PMID:40473449

Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies., PMID:40436467

An evaluation of recaticimab for the treatment of hypercholesterolemia., PMID:40380894

Engineering an alkaline-stable protein A through rational design strategies., PMID:40367905

Lipoprotein(a) Measurement in Lipoprotein Apheresis: Time to Change?, PMID:40181783

Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review., PMID:40167967

Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer., PMID:40155220

Development of a fully automated latex-enhanced immunoturbidimetric method for quantitative serum Lp(a) measurement., PMID:40045089

Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082

Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects., PMID:39928714

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials., PMID:39877671

Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches., PMID:39781530

Implementation of new Westgard rules suggested by the Westgard Advisor software for five immunological parameters., PMID:39703760

An up-to-date review of emerging biologic therapies for hypercholesterolemia., PMID:39668448

Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin., PMID:39647781

The path of GPR87: from a P2Y-like receptor to its role in cancer progression., PMID:39641798

Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab., PMID:39561225

Laboratory parameters-based logistic regression models for rapid screening of thyroid nodules., PMID:39544979

Prevention and alleviation of allergic rhinitis by oral administration of Lacticaseibacillus paracasei GOLDGUT-Lpc969., PMID:39403377

Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients., PMID:39385797

The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report., PMID:39342791

Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study., PMID:39223063

New promises and challenges in the treatment of advanced non-small-cell lung cancer., PMID:39121882

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study., PMID:39054476

Advances in nucleic acid-targeted therapies for cardiovascular disease prevention., PMID:38970537

Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study., PMID:38929525

[Distribution and influencing factors of lipoprotein (a) levels in non-arteriosclerotic cardiovascular disease population in China]., PMID:38889976

Atherothrombotic Risk Factors in Patients With Rheumatoid Arthritis., PMID:38846255

Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells., PMID:38837511

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials., PMID:38750034

Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study., PMID:38701823

Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings., PMID:38691317

Targeting AQP9 enhanced the anti-TNF therapy response in Crohn's disease by inhibiting LPA-hippo pathway., PMID:38583685

The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better., PMID:38576462

Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES., PMID:38501249

Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus., PMID:38436267

Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary., PMID:38414008

Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups., PMID:38375817

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial., PMID:38346853

Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis., PMID:38336118

The impacts of biologic treatment on metabolic profiling in psoriasis., PMID:38284208

Lipid profile and NT-proBNP changes from pre-clinical to established rheumatoid arthritis: A 12 years follow-up explorative study., PMID:38161051

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts., PMID:37766235

Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models., PMID:37550785

Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases., PMID:37513831

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention., PMID:37486464

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results., PMID:37390764

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629

Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials., PMID:37335067

Datasheet

Document Download

Anti-LPA Antibody (R1L65).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-LPA Antibody (R1L65) [RHC33401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only